- Home
- CMPX vs TLSI Comparison
CMPX vs TLSI Comparison
Compare CMPX & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- TLSI
- Stock Information
- Founded
- CMPX 2014
- TLSI 2010
- Country
- CMPX United States
- TLSI United States
- Employees
- CMPX N/A
- TLSI N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- CMPX Health Care
- TLSI Health Care
- Exchange
- CMPX Nasdaq
- TLSI Nasdaq
- Market Cap
- CMPX 291.8M
- TLSI 204.0M
- IPO Year
- CMPX N/A
- TLSI N/A
- Fundamental
- Price
- CMPX $2.62
- TLSI $4.90
- Analyst Decision
- CMPX Strong Buy
- TLSI Strong Buy
- Analyst Count
- CMPX 9
- TLSI 5
- Target Price
- CMPX $12.67
- TLSI $10.90
- AVG Volume (30 Days)
- CMPX 940.2K
- TLSI 152.1K
- Earning Date
- CMPX 08-11-2025
- TLSI 08-13-2025
- Dividend Yield
- CMPX N/A
- TLSI N/A
- EPS Growth
- CMPX N/A
- TLSI N/A
- EPS
- CMPX N/A
- TLSI N/A
- Revenue
- CMPX $850,000.00
- TLSI $32,141,000.00
- Revenue This Year
- CMPX N/A
- TLSI $55.52
- Revenue Next Year
- CMPX N/A
- TLSI $54.76
- P/E Ratio
- CMPX N/A
- TLSI N/A
- Revenue Growth
- CMPX N/A
- TLSI 46.20
- 52 Week Low
- CMPX $0.77
- TLSI $3.50
- 52 Week High
- CMPX $4.08
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- CMPX 62.96
- TLSI 41.80
- Support Level
- CMPX $2.50
- TLSI $5.18
- Resistance Level
- CMPX $2.71
- TLSI $5.63
- Average True Range (ATR)
- CMPX 0.19
- TLSI 0.35
- MACD
- CMPX 0.00
- TLSI -0.03
- Stochastic Oscillator
- CMPX 72.00
- TLSI 10.63
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.